Microcap Ledger Ensysce Biosciences, Inc. $ENSC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- La Jolla, CA
- Fiscal year end
- December 31
- Shares outstanding
- 19,456,794 [10-Q 2026-08-13]
What the company doesAI summary of filing
Ensysce Biosciences is a clinical-stage pharmaceutical company developing product candidates designed to improve the safety of prescription drugs by reducing abuse and overdose potential. The company's lead candidates are PF614, a chemically modified oxycodone prodrug using its TAAP (Trypsin Activated Abuse Protection) platform, and PF614-MPAR, which combines PF614 with nafamostat to provide overdose protection. Both candidates are in clinical development, with PF614 currently in Phase 3 trials for acute pain and PF614-MPAR having received FDA Breakthrough Therapy designation. The company generates no revenue and funds operations through convertible notes and equity offerings. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $2.13M | −$6.13M | −$5.46M | $676.7K | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $5.07M | −$10.18M | −$7.81M | $4.31M | [10-K 2026-03-30] |
| FY ended Dec 2024 | $5.21M | −$7.99M | −$7.50M | $3.50M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$2.73M
- Cash runway Estimate
- ~0.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 19,574,014 | [10-Q 2024-11-12] |
| 2025-03-07 | 1,405,134 | [10-K 2025-03-10] |
| 2025-05-08 | 2,370,698 | [10-Q 2025-05-13] |
| 2025-08-12 | 2,968,444 | [10-Q 2025-08-13] |
| 2025-11-10 | 3,541,262 | [10-Q 2025-11-14] |
| 2026-03-27 | 9,277,819 | [10-K 2026-03-30] |
| 2026-05-14 | 14,694,492 | [10-Q 2026-05-15] |
| 2026-08-12 | 19,456,794 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-06-04; declared effective 2026-06-26 [S-3 2026-06-04]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-05-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-22] |
| 2026-02-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-27] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-07 | Gower Bob G | buy | 400,000 | $0.49 | [4 2026-08-18] |
| 2026-04-23 | Gower Bob G | buy | 508,614 | $0.48 | [4 2026-08-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Charter, bylaws or fiscal year change |
| 2026-08-25 | 8-K | Other events |
| 2026-08-24 | 8-K | Other events |
| 2026-08-18 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-06 | 8-K | Material agreement entered; Acquisition or disposition completed; Unregistered sale of equity |
| 2026-07-15 | 8-K | Director or officer change |
| 2026-06-04 | S-3 | Registration statement |
| 2026-05-22 | 8-K | Listing notice or transfer |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-15 | 8-K | Results of operations |
Alerts for $ENSC
Email me when Ensysce Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.